Simon Wheeler to be co-opted as independent director and chair the board of directors of TheraVet
Nesya Goris and Christian Schirvel will also join the board as independent director and independent observer respectively
GOSSELIES, Wallonie, Belgium, December 16, 2021– (BUSINESS WIRE) – Regulatory news:
Theravet (ISIN: BE0974387194 – mnemonic: ALVET), a biotechnology company specializing in bone and joint treatments for animals, is strengthening its corporate governance by co-opting two new independent directors (Simon Wheeler and Nesya Goris) and an independent observer (Christian Schirvel) . Their appointment to the board of directors is subject to the approval of the shareholders at the next general meeting of shareholders of the Company. Simon Wheeler will also replace Lotfi Yelles Chaouche as Chairman of the Board of TheraVet.
Enrico Bastianelli, CEO of TheraVet, said: “We are delighted that three new independent members of the quality of Simon Wheeler, Nesya Goris and Christian Schirvel are joining our Board of Directors. with their expertise in animal health, will be invaluable assets in the pursuit of our strategic development. “
Dr Simon Wheeler, BVSc, PhD, said: “It is an honor to join the Board of Directors of TheraVet. The team has already accomplished great things under the leadership of Enrico Bastianelli and the governance of the Board of Directors, chaired by Lotfi Yelles Chaouche. We are rightly excited about the future of TheraVet as the Company enters a commercialization phase while continuing the clinical development of its veterinary product portfolio. I have no doubts that the hard work of the TheraVet team will continue to produce fantastic results for pets and their owners, in association with the veterinary professionals who provide them with high quality clinical care.“
Dr Nesya Goris, Doctor of Veterinary Sciences, said: “The treatments that TheraVet develops and offers in the field of osteoarticular diseases have the potential to have a significant impact on the quality of life of cats, dogs and horses and it is a pleasure for me to be able to witness and, hopefully, help with that. story. “
Dr Christian Schirvel, DVM, MSc, said: “It is with great pleasure that I join the Board of Directors of TheraVet. I have worked in the veterinary pharmaceutical industry for over 30 years and have contributed to the realization of various projects related to surgery in general, oncology and osteoarthritis: high growth segments responding to the needs in which TheraVet is developing its activity. I will therefore bring my knowledge of the animal health market and those who participate in it, with the aim of helping this promising biotechnology company to make the right strategic decisions in terms of developing its activity, and selecting which projects to focus on. focus, establish partnerships and determine its current and future approach to product marketing. “
Biographies of new board members
Dr Simon Wheeler, BVSc, PhD, DECVN, MBA, FRCVS, is an expert in animal health and veterinary medicine. He has more than 20 years of experience in large pharmaceutical groups in which he has held numerous management positions, and has worked for more than 20 years in academia. Dr Wheeler holds a doctorate in veterinary medicine from the Royal Veterinary College and an MBA from the Open University Business School. He is Managing Director of Veterinary Neurology Ltd and spent 10 years with Novartis Animal Health, including a four-year period with Novartis Venture Fund. Dr Wheeler was previously chairman of the academic board of the European School of Veterinary Studies and a director of Anifera Ltd, a start-up in the field of antimicrobial resistance. He consults on clinical veterinary neurology patients.
Dr Nesya Goris, PhD, is co-founder and director of development at ViroVet. She holds a master’s degree in science from the University of Louvain and a doctorate in veterinary science from the University of Ghent. After starting her career at the Belgian Reference Laboratory for Animal Diseases, she became Chief Scientist at Okapi Sciences for six years before being taken over by Aratana Therapeutics, where she was appointed VP Discovery Research and contributed to the commercial launch of Galliprant, a treatment for canine osteoarthritis. Currently, Dr Goris combines his role at ViroVet with that of Technical and Regulatory Director at Animab BV. She is also a member of the board of directors of Flanders Vaccine, editor of the academic journal Antiviral Research and lecturer at the University of Louvain in Belgium.
Dr Christian Schirvel DVM., MSc, is very experienced in the field of animal health, having spent more than 30 years in pharmaceutical groups such as Mérieux, Merial, Vétoquinol, Novartis and Elanco. Prior to joining the Board of TheraVet, he was responsible for business development and licensing (EMEA and APAC) at Elanco. He also spent nearly seven years with Swiss pharmaceutical group Novartis Animal Health as business development and licensing manager for antiparasitics and therapeutic products. Previously in his career, Christian spent nine years at Rhône Mérieux, occupying several key positions including that of Head of Strategic Development. He is also an independent consultant (Vel-Vet AH Consulting) for small and medium-sized animal health companies, supporting them in defining their strategy in general. He graduated from the University of Liège in Belgium.
About TheraVet SA
TheraVet is a veterinary biotechnology company specializing in bone and joint treatments for animals. The Company develops targeted, safe and effective treatments to improve the quality of life of animals suffering from osteoarticular diseases. For pet owners, the health of their animals is a major concern and TheraVet’s mission is to meet the need for innovative and curative treatments. TheraVet works in close collaboration with international opinion leaders in order to provide a more effective response to the ever increasing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, its head office is in Gosselies, Belgium, and it has a subsidiary in the United States.
For more information, visit the TheraVet website or follow us on LinkedIn / Facebook / Twitter.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20211215005910/en/
Phone: +32 71 96 00 43
Chief executive officer
Investor Relations and Financial Communication
Louis Tilquin / Olivier Bricaud
Phone: +33 1 44 71 94 94
Arthur Rouillé / Ambre Delval
Phone: +33 1 44 71 00 15